Ipamorelin GHSR-1a Research: GH Deficiency Cell Models and Receptor Studies
Ipamorelin is a research compound studied in cell-based assay formats for its selective GHSR-1a (class A GPCR) Gq/calcium mobilisation. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
Receptor Pharmacology and Mechanism of Action
GHSR-1a Receptor Selectivity
Ipamorelin acts via selective GHSR-1a (class A GPCR) Gq/calcium mobilisation. Competitive radioligand binding assays and functional cell-based assays demonstrate high selectivity for the growth hormone secretagogue receptor subtype 1a compared to other ghrelin receptor variants. In vitro binding studies utilising [125I]-labeled ghrelin as a radioligand show ipamorelin displacement with nanomolar affinity constants, indicating potent receptor engagement.
Cell line studies employing HEK293 cells transfected with human GHSR-1a receptors reveal ipamorelin's mechanism involves G-protein coupled receptor activation leading to phospholipase C stimulation. This cascade triggers inositol trisphosphate (IP3) formation and subsequent calcium release from intracellular stores, measurable through fluorescent calcium indicator assays.
G-Protein Signalling Pathways
Functional assays in GHSR-1a expressing cell systems demonstrate ipamorelin's engagement of Gq/G11 protein subunits. Calcium mobilisation assays using Fura-2 or Fluo-4 indicators show dose-dependent intracellular calcium elevation following ipamorelin administration. The compound exhibits EC50 values in the nanomolar range across multiple cell model systems, indicating high potency for receptor activation.
Downstream signalling analysis reveals activation of protein kinase C (PKC) pathways and cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) phosphorylation in responsive cell lines. These molecular events occur within minutes of receptor engagement, demonstrating the rapid kinetics of ipamorelin-mediated cellular responses.
Cell Model Systems and In Vitro Assays
Primary Cell Culture Models
Research utilising primary pituitary cell cultures from animal models provides insights into ipamorelin's receptor pharmacology in physiologically relevant cellular contexts. These ex vivo preparations maintain native receptor expression patterns and intracellular signalling machinery, offering valuable data on compound activity in differentiated cell populations.
Calcium imaging techniques applied to primary pituitary cultures reveal heterogeneous cellular responses to ipamorelin exposure, reflecting the diverse cell populations present in these preparations. Single-cell analysis demonstrates variable response amplitudes and kinetics, providing data on cellular heterogeneity in receptor expression and signalling capacity.
Immortalised Cell Line Applications
HEK293 and CHO cell lines stably transfected with GHSR-1a constructs serve as standardised platforms for ipamorelin receptor pharmacology studies. These systems enable reproducible assessment of binding kinetics, receptor occupancy, and functional responses under controlled experimental conditions.
Whole-cell patch-clamp electrophysiology in transfected cell lines reveals ipamorelin's effects on membrane conductances and ion channel activity downstream of receptor activation. These studies demonstrate modulation of calcium-activated potassium channels and L-type calcium channels following GHSR-1a engagement.
Binding Affinity and Kinetic Studies
Radioligand Binding Analysis
Saturation binding experiments utilising [125I]-ghrelin in membrane preparations from GHSR-1a expressing cells establish ipamorelin's competitive binding characteristics. Scatchard plot analysis reveals binding affinity constants (Kd) in the low nanomolar range, indicating high-affinity receptor interaction.
Competition binding assays demonstrate ipamorelin's ability to displace radiolabeled ghrelin from GHSR-1a binding sites with IC50 values consistently below 100 nanomolar across multiple experimental systems. These data support the compound's selective receptor engagement profile.
Enzyme Kinetic Parameters
Functional assays measuring adenylyl cyclase activity and phospholipase C activation reveal ipamorelin's enzyme kinetic properties. Michaelis-Menten analysis of dose-response curves provides Vmax and Km values for downstream enzyme activation, characterising the compound's efficacy and potency parameters.
Time-course studies of second messenger generation demonstrate peak responses occurring within 30-60 seconds of ipamorelin application, followed by sustained elevation lasting several minutes. These kinetic profiles inform optimal experimental timing for functional endpoint measurements.
Research Summary
In vitro research demonstrates ipamorelin's selective GHSR-1a receptor agonism through multiple experimental approaches. Binding studies confirm nanomolar affinity for the target receptor, while functional assays reveal potent activation of Gq/G11-mediated signalling pathways. Cell model systems ranging from primary cultures to transfected cell lines provide consistent evidence for calcium mobilisation and downstream kinase activation. These receptor pharmacology data establish ipamorelin as a valuable research tool for investigating GHSR-1a function and growth hormone secretagogue mechanisms in controlled laboratory environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML